Drug Cuts Cholesterol Beyond What Statins Can Do?
Whether it also prevents heart attacks and strokes isn't known yet, experts say
By Steven Reinberg
SUNDAY, March 30, 2014 (HealthDay News) -- Two studies find that an experimental cholesterol-lowering drug is effective when combined with statins and beats another add-on drug when it comes to helping hard-to-treat patients.
The drug, evolocumab, is an injectable antibody that works differently than statins by increasing the ability of the liver to clear LDL ("bad") cholesterol from the blood. The value of this drug is that it lowers cholesterol in patients who cannot tolerate statins or for whom statins don't lower cholesterol enough.
"These two new studies provide further evidence of the efficacy of evolocumab for lowering LDL cholesterol in statin-treated and in statin-intolerant patients. The results are impressive," said Dr. Gregg Fonarow, a professor of medicine at the University of California, Los Angeles, who had no part in either study.
Both studies were funded by Amgen, the maker of evolocumab, and the results were scheduled to be presented Sunday at the American College of Cardiology's annual meeting, in Washington, D.C.
"Evolocumab may provide an effective option for patients needing additional LDL-cholesterol lowering," said Dr. Jennifer Robinson, director of the Prevention Intervention Center at the University of Iowa College of Public Health, and lead author of the first study.
In that trial, evolocumab was added to statins such as atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor). The trial, which involved almost 1,900 patients, also compared the effectiveness of evolucumab when pitted against ezetimibe (Zetia), another drug that can be added to statin therapy to further reduce cholesterol.
"Evolocumab further reduces LDL cholesterol by about 65 to 75 percent when added to a statin. Evolocumab reduces LDL cholesterol more than ezetimibe -- about a 15 to 20 percent additional LDL-cholesterol reduction, when added to statin," Robinson said.
"A [different] trial is under way to determine if the addition of evolocumab will further reduce heart attack and stroke in statin-treated patients with cardiovascular disease," she added.
For the second trial, a research team led by Dr. Erik S.G. Stroes, chair of the department of vascular medicine at the Academic Medical Center in Amsterdam, found that evolocumab was more effective than Zetia in lowering cholesterol beyond what could be achieved by statins alone.